echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer/BioNTech submits to the FDA the marketing application for the third dose of mRNA COVID-19 vaccine

    Pfizer/BioNTech submits to the FDA the marketing application for the third dose of mRNA COVID-19 vaccine

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On August 25, Pfizer/BioNTech jointly announced that it had submitted a rolling submission of the third dose of COMIRNATY (COVID-19 vaccine, mRNA) to the FDA for the supplementary license application (sBLA) for the enhanced injection of biological products


    This sBLA data submission is based on data from a phase III clinical trial.


    In subjects who had no evidence of SARS-CoV-2 infection within 1 month of the third dose of vaccine, COMIRNATY induced the production of powerful neutralizing antibodies against the wild-type strain


    In addition, after the third dose, 99.


    Pfizer and BioNTech plan to submit these data to peer-reviewed journals in the next few weeks and submit these data to the European Medicines Agency (EMA) and regulatory agencies in other countries and regions around the world


    The third dose of COMIRNATY booster injection has not been widely used in the United States.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.